Cellular and molecular biology of myocardial hypertrophy

Christensen group

We aim to develop novel therapeutic approaches and better diagnostic tools for heart failure through new knowledge about molecular mechanisms involved.

 

 

In particular, we study the concept that cardiac proteoglycans are active and central signal mediators of myocardial remodeling. Proteoglycans are highly glycosylated proteins localized to the cell membranes and the extracellular matrix (ECM).

By examining the unique properties of transmembrane proteoglycans we have discovered that the proteoglycan syndecan-4 is a mechanical stress-sensor in cardiomyocytes and cardiac fibroblasts and involved in signalling causing heart failure. One important ECM-localized molecule is lumican and we have shown that it regulates cardiac remodelling and heart failure. Currently we are testing promising drugs to treat heart failure by targeting mechanisms identified by our group. The ultimate goal of our research is to improve the well-being and prognosis of patients.

 

The work in this group is supervised by professor Geir Christensen. The group consists of scientists from IEMR that collaborate closely with Department of Thoracic Surgery (Professor Theis Tønnessen) and Department of Cardiology at Oslo University Hospital (Professor Lars Gullestad). In addition to top-of-the-range international scientists from Harvard, Johns Hopkins, among others, who are world leading in their field.

Group members

Andreas Romaine

Postdoctoral fellow

Athiramol Sasi

Researcher without PhD

Camilla Udjus

Doctoral Research Fellow

Francesca Lockwood

Doctoral Research Fellow

Maria Vistnes

Postdoctoral fellow, Resident

Latest publications

view all >
Myhre PL, Ottesen AH, Faaren AL, Tveit SH, Springett J, Pyylampi J, Stridsberg M, Christensen G, Høiseth AD, Omland T, Røsjø H (2021)
Performance of a Novel Research-Use-Only Secretoneurin ELISA in Patients with Suspected Acute Coronary Syndrome: Comparison with an Established Secretoneurin Radioimmunoassay
Cardiology, 1-9
PubMed 34284402 DOI 10.1159/000517444
Thorlacius EM, Vistnes M, Ojala T, Keski-Nisula J, Molin M, Romlin BS, Synnergren M, Ricksten SE, Wåhlander H, Castellheim A (2021)
Levosimendan Versus Milrinone and Release of Myocardial Biomarkers After Pediatric Cardiac Surgery: Post Hoc Analysis of Clinical Trial Data
Pediatr Crit Care Med, 22 (7), e402-e409
PubMed 33739957 DOI 10.1097/PCC.0000000000002712
Rutkovskiy A, Lyngbakken MN, Dahl MB, Bye A, Pedersen MH, Wisløff U, Christensen G, Høiseth AD, Omland T, Røsjø H (2021)
Circulating MicroRNA-210 Concentrations in Patients with Acute Heart Failure: Data from the Akershus Cardiac Examination 2 Study
Clin Chem, 67 (6), 889-898
PubMed 33783502 DOI 10.1093/clinchem/hvab030
Nordén ES, Bendiksen BA, Andresen H, Bergo KK, Espe EK, Hasic A, Hauge-Iversen IM, Veras I, Hussain RI, Sjaastad I, Christensen G, Cataliotti A (2021)
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
ESC Heart Fail, 8 (2), 918-927
PubMed 33497525 DOI 10.1002/ehf2.13177
Berge K, Lyngbakken MN, Myhre PL, Brynildsen J, Røysland R, Strand H, Christensen G, Høiseth AD, Omland T, Røsjø H (2020)
High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide in acute heart failure: Data from the ACE 2 study
Clin Biochem, 88, 30-36
PubMed 33245872 DOI 10.1016/j.clinbiochem.2020.11.009
view all >

Group news

Doctoral Thesis

Doctoral Thesis, Andreas Romaine

13/02/2020